Powered by

Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results

Nov 02, 2020 - Business Wire
Mergers and Acquisitions-Event Announcements

Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended September 30, 2020.

During the second quarter of fiscal year 2020, the Company achieved a number of significant operational and commercial planning milestones in preparation for the U.S. Food and Drug Administration's (FDA) decision on the New Drug Application (NDA) for vibegron in overactive bladder (OAB) by the assigned Prescription Drug User Fee Act (PDUFA) goal date of December 26th. This incl...